{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:06:05Z","timestamp":1771527965243,"version":"3.50.1"},"reference-count":123,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972643"],"award-info":[{"award-number":["81972643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Science and Technology Project","doi-asserted-by":"publisher","award":["2018JY0079"],"award-info":[{"award-number":["2018JY0079"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Science and Technology Project","doi-asserted-by":"publisher","award":["2021YJ0201"],"award-info":[{"award-number":["2021YJ0201"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CSCR"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Mesenchymal stem cells (MSCs) are getting attention in the field of cancer immunotherapy.\nThe main effects of MSCs on tumors are homing and regulation of inflammatory and immune responses.\nIndeed, cancer immunotherapy has become a promising treatment and MSCs play a potential role in regulating\nthe efficacy of immunotherapy. In addition, MSCs are an ideal carrier for immunomodulatory protein\ntransmission. As such MSCs combined with immunotherapy drugs could act synergistically against\ntumors, throwing a great impact on cancer therapy. And MSCs may have potential in the treatment of\ncytokine storm or cytokine release syndrome (CRS). It is assumed that MSCs can form chimeric antigen\nreceptor MSCs (CAR-MSCs). Whether CAR-MSCs can provide a new idea of cancer immunotherapy is\nunknown. It is a prime time to review the latest progress of MSCs in cancer immunotherapy, in order to\nclarify to fully understand the role of MSCs in cancer therapy in clinical practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574888x18666230103120302","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T07:18:20Z","timestamp":1672816700000},"page":"1056-1068","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Mesenchymal Stem Cells in Cancer Immunotherapy"],"prefix":"10.2174","volume":"18","author":[{"given":"Yueshui","family":"Zhao","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"},{"name":"Department of Pharmacy, People\u2019s Hospital of Nanbu County, Nanchong, Sichuan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukuan","family":"Du","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wu","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglian","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Data\nScience, The Chinese University of Hong Kong, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, The\nAffiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Deng","sequence":"additional","affiliation":[{"name":"Medical\nCosmetology Center, Affiliated of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, PR\nChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical\nCosmetology Center, Affiliated of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, PR\nChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Zou","sequence":"additional","affiliation":[{"name":"Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People\u2019s\nHospital, Shenzhen, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[{"name":"Medical\nCosmetology Center, Affiliated of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, PR\nChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University,\nLuzhou, Sichuan, China"},{"name":"Cell Therapy &amp; Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2174\/157488806778226821","volume":"1","author":"Porada C.","year":"2006","unstructured":"Porada C.; Zanjani E.; Almeida-Porada G.; Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006,1(3),365-369","journal-title":"Curr Stem Cell Res Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000203993","volume":"94","author":"Sim\u00f5es B.P.","year":"1995","unstructured":"Sim\u00f5es B.P.; Tone L.G.; Zago M.A.; Figueiredo M.S.; Splenic function in acute leukemia. Acta Haematol 1995,94(3),123-127","journal-title":"Acta Haematol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"Kennedy L.B.","year":"2020","unstructured":"Kennedy L.B.; Salama A.K.S.; A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020,70(2),86-104","journal-title":"CA Cancer J Clin"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00432-019-02859-6","volume":"145","author":"Meng M.Y.","year":"2019","unstructured":"Meng M.Y.; Li L.; Wang W.J.; Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo. J Cancer Res Clin Oncol 2019,145(5),1133-1146","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"728190","DOI":"10.3389\/fimmu.2021.728190","volume":"12","author":"Li A.","year":"2021","unstructured":"Li A.; Guo F.; Pan Q.; Mesenchymal stem cell therapy: Hope for patients with systemic lupus erythematosus. Front Immunol 2021,12,728190","journal-title":"Front Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"724380","DOI":"10.3389\/fimmu.2021.724380","volume":"12","author":"Murata M.","year":"2021","unstructured":"Murata M.; Teshima T.; Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products. Front Immunol 2021,12,724380","journal-title":"Front Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.canlet.2017.11.025","volume":"414","author":"Mohr A.","year":"2018","unstructured":"Mohr A.; Zwacka R.; The future of mesenchymal stem cell-based therapeutic approaches for cancer \u2013 From cells to ghosts. Cancer Lett 2018,414,239-249","journal-title":"Cancer Lett"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1667\/RR1995.1","volume":"173","author":"Tomita M.","year":"2010","unstructured":"Tomita M.; Maeda M.; Maezawa H.; Usami N.; Kobayashi K.; Bystander cell killing in normal human fibroblasts is induced by synchrotron X-ray microbeams. Radiat Res 2010,173(3),380-385","journal-title":"Radiat Res"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"Oun R.","year":"2018","unstructured":"Oun R.; Moussa Y.; Wheate N.; The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans 2018,47(19),6645-6653","journal-title":"Dalton Trans"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/cgt.2016.35","volume":"23","author":"Mohammadi M.","year":"2016","unstructured":"Mohammadi M.; Jaafari M.R.; Mirzaei H.R.; Mirzaei H.; Mesenchymal stem cell: A new horizon in cancer gene therapy. Cancer Gene Ther 2016,23(9),285-286","journal-title":"Cancer Gene Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdermsci.2016.11.005","volume":"86","author":"Motegi S.","year":"2017","unstructured":"Motegi S.; Ishikawa O.; Mesenchymal stem cells: The roles and functions in cutaneous wound healing and tumor growth. J Dermatol Sci 2017,86(2),83-89","journal-title":"J Dermatol Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/14712598.2016.1196179","volume":"16","author":"Hagenhoff A.","year":"2016","unstructured":"Hagenhoff A.; Bruns C.J.; Zhao Y.; Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opin Biol Ther 2016,16(9),1079-1092","journal-title":"Expert Opin Biol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.mayocpiqo.2020.04.006","volume":"4","author":"Al-kharboosh R.","year":"2020","unstructured":"Al-kharboosh R.; ReFaey K; Lara-Velazquez M; Grewal SS; Imitola J; Qui\u00f1ones-Hinojosa A; Inflammatory mediators in glioma microenvironment play a dual role in gliomagenesis and mesenchymal stem cell homing: Implication for cellular therapy. Mayo Clin Proc Innov Qual Outcomes 2020,4(4),443-459","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/0929867323666151217122033","volume":"23","author":"Mirzaei H.","year":"2016","unstructured":"Mirzaei H.; Sahebkar A.; Avan A.; Application of mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents. Curr Med Chem 2016,23(5),455-463","journal-title":"Curr Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/jnen\/nlz016","volume":"78","author":"Li M.","year":"2019","unstructured":"Li M.; Zeng L.; Liu S.; Transforming growth factor-\u03b2 promotes homing and therapeutic efficacy of human mesenchymal stem cells to glioblastoma. J Neuropathol Exp Neurol 2019,78(4),315-325","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cbin.10378","volume":"39","author":"Naderi-Meshkin H.","year":"2015","unstructured":"Naderi-Meshkin H.; Bahrami A.R.; Bidkhori H.R.; Mirahmadi M.; Ahmadiankia N.; Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy. Cell Biol Int 2015,39(1),23-34","journal-title":"Cell Biol Int"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"Karp J.M.","year":"2009","unstructured":"Karp J.M.; Leng Teo G.S.; Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009,4(3),206-216","journal-title":"Cell Stem Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Cao X.; Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med 2016,94(5),509-522","journal-title":"J Mol Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bmhimx.2016.10.003","volume":"73","author":"Castro-Manrreza M.E.","year":"2016","unstructured":"Castro-Manrreza M.E.; Participation of mesenchymal stem cells in the regulation of immune response and cancer development. Bol M\u00e9d Hosp Infant M\u00e9xico 2016,73(6),380-387","journal-title":"Bol M\u00e9d Hosp Infant M\u00e9xico"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.vetimm.2017.07.013","volume":"191","author":"Chae H.K.","year":"2017","unstructured":"Chae H.K.; Song W.J.; Ahn J.O.; Immunomodulatory effects of soluble factors secreted by feline adipose tissue-derived mesenchymal stem cells. Vet Immunol Immunopathol 2017,191,22-29","journal-title":"Vet Immunol Immunopathol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/path.5357","volume":"250","author":"Galland S.","year":"2020","unstructured":"Galland S.; Stamenkovic I.; Mesenchymal stromal cells in cancer: A review of their immunomodulatory functions and dual effects on tumor progression. J Pathol 2020,250(5),555-572","journal-title":"J Pathol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4252\/wjsc.v12.i9.1032","volume":"12","author":"Song Y.","year":"2020","unstructured":"Song Y.; Lim J.Y.; Lim T.; Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms. World J Stem Cells 2020,12(9),1032-1049","journal-title":"World J Stem Cells"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.it.2007.03.001","volume":"28","author":"Uccelli A.","year":"2007","unstructured":"Uccelli A.; Pistoia V.; Moretta L.; Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol 2007,28(5),219-226","journal-title":"Trends Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/ijms17050650","volume":"17","author":"Fan L.","year":"2016","unstructured":"Fan L.; Hu C.; Chen J.; Cen P.; Wang J.; Li L.; Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci 2016,17(5),650","journal-title":"Int J Mol Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/jcp.30038","volume":"236","author":"Moloudizargari M.","year":"2021","unstructured":"Moloudizargari M.; Govahi A.; Fallah M.; Rezvanfar M.A.; Asghari M.H.; Abdollahi M.; The mechanisms of cellular crosstalk between mesenchymal stem cells and natural killer cells: Therapeutic implications. J Cell Physiol 2021,236(4),2413-2429","journal-title":"J Cell Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1574888X10666150904114035","volume":"11","year":"2016","unstructured":"\u00d0oki\u0107 JM, Tomi\u0107 SZ, \u010coli\u0107 MJ. Cross-talk between mesenchymal stem\/stromal cells and dendritic cells. Curr Stem Cell Res Ther 2016,11(1),51-65","journal-title":"Curr Stem Cell Res Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"624746","DOI":"10.3389\/fimmu.2021.624746","volume":"12","author":"Luque-Campos N.","year":"2021","unstructured":"Luque-Campos N.; Bustamante-Barrientos F.A.; Pradenas C.; The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming. Front Immunol 2021,12,624746","journal-title":"Front Immunol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"37566","DOI":"10.1038\/srep37566","volume":"6","author":"Deng Y.","year":"2016","unstructured":"Deng Y.; Zhang Y.; Ye L.; Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. Sci Rep 2016,6(1),37566","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3390\/ijms22052472","volume":"22","author":"Harrell C.R.","year":"2021","unstructured":"Harrell C.R.; Djonov V.; Volarevic V.; The cross-talk between mesenchymal stem cells and immune cells in tissue repair and regeneration. Int J Mol Sci 2021,22(5),2472","journal-title":"Int J Mol Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/cdd.2012.26","volume":"19","author":"Li W.","year":"2012","unstructured":"Li W.; Ren G.; Huang Y.; Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ 2012,19(9),1505-1513","journal-title":"Cell Death Differ"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e48052","DOI":"10.15252\/embr.201948052","volume":"21","author":"Court A.C.","year":"2020","unstructured":"Court A.C.; Le-Gatt A.; Luz-Crawford P.; Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. EMBO Rep 2020,21(2),e48052","journal-title":"EMBO Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13287-019-1307-9","volume":"10","author":"Luz-Crawford P.","year":"2019","unstructured":"Luz-Crawford P.; Hernandez J.; Djouad F.; Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer. Stem Cell Res Ther 2019,10(1),232","journal-title":"Stem Cell Res Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.1038\/s41598-021-90115-8","volume":"11","author":"Do J.","year":"2021","unstructured":"Do J.; Zwick D.; Kenyon J.D.; Mesenchymal stromal cell mitochondrial transfer to human induced T-regulatory cells mediates FOXP3 stability. Sci Rep 2021,11(1),10676","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pharmthera.2019.04.005","volume":"200","author":"Li P.","year":"2019","unstructured":"Li P.; Gong Z.; Shultz L.D.; Ren G.; Mesenchymal stem cells: From regeneration to cancer. Pharmacol Ther 2019,200,42-54","journal-title":"Pharmacol Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fncel.2017.00312","volume":"11","author":"Bajetto A.","year":"2017","unstructured":"Bajetto A.; Pattarozzi A.; Corsaro A.; Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front Cell Neurosci 2017,11,312","journal-title":"Front Cell Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3389\/fimmu.2018.01658","volume":"9","author":"Yan L.","year":"2018","unstructured":"Yan L.; Zheng D.; Xu R.H.; Critical role of tumor necrosis factor signaling in mesenchymal stem cell-based therapy for autoimmune and inflammatory diseases. Front Immunol 2018,9,1658","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4252\/wjsc.v13.i8.971","volume":"13","author":"Razazian M.","year":"2021","unstructured":"Razazian M.; Khosravi M.; Bahiraii S.; Uzan G.; Shamdani S.; Naserian S.; Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells. World J Stem Cells 2021,13(8),971-984","journal-title":"World J Stem Cells"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7314016","volume":"2016","author":"Trivanovi\u0107 D","year":"2016","unstructured":"Trivanovi\u0107 D; Krsti\u0107 J; Djordjevi\u0107 IO; The roles of mesenchymal stromal\/stem cells in tumor microenvironment associated with inflammation. Mediators Inflamm 2016,2016,1-14","journal-title":"Mediators Inflamm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41419-019-1622-1","volume":"10","author":"Chen J.","year":"2019","unstructured":"Chen J.; Ji T.; Wu D.; Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin \u03b15 in hepatocellular carcinoma. Cell Death Dis 2019,10(6),425","journal-title":"Cell Death Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1111\/jcmm.15668","volume":"24","author":"Liu Q.W.","year":"2020","unstructured":"Liu Q.W.; Li J.Y.; Zhang X.C.; Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour\u2010bearing mice. J Cell Mol Med 2020,24(18),10525-10541","journal-title":"J Cell Mol Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/stem.1594","volume":"32","author":"Nasuno M","year":"2014","unstructured":"Nasuno M; Arimura Y; Nagaishi K; Isshiki H; Onodera K; Nakagaki S; Watanabe S; Idogawa M; Yamashita K; Naishiro Y; Adachi Y; Suzuki H; Fujimiya M; Imai K; Shinomura Y.; Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Stem Cells 2014,32(4),913-925","journal-title":"Stem Cells"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/ijc.32230","volume":"145","author":"Einem J.C.","year":"2019","unstructured":"Einem J.C.; Guenther C.; Volk H.D.; Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1\/2 TREAT\u2010ME\u20101 trial. Int J Cancer 2019,145(6),1538-1546","journal-title":"Int J Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bbrc.2014.03.051","volume":"446","author":"Lee M.","year":"2014","unstructured":"Lee M.; Jeong S.Y.; Ha J.; Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem Biophys Res Commun 2014,446(4),983-989","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","volume":"16","author":"Ridge S.M.","year":"2017","unstructured":"Ridge S.M.; Sullivan F.J.; Glynn S.A.; Mesenchymal stem cells: Key players in cancer progression. Mol Cancer 2017,16(1),31","journal-title":"Mol Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12015-015-9614-8","volume":"11","author":"Weinstock A.","year":"2015","unstructured":"Weinstock A.; Pevsner-Fischer M.; Porat Z.; Selitrennik M.; Zipori D.; Cultured mesenchymal stem cells stimulate an immune response by providing immune cells with toll-like receptor 2 ligand. Stem Cell Rev 2015,11(6),826-840","journal-title":"Stem Cell Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/jitc-2019-000164","volume":"8","author":"Mao J.","year":"2020","unstructured":"Mao J.; Cao M.; Zhang F.; Peritumoral administration of IFN\u03b2 upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model. J Immunother Cancer 2020,8(1),e000164","journal-title":"J Immunother Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13287-019-1320-z","volume":"10","author":"Du L.","year":"2019","unstructured":"Du L.; Liang Q.; Ge S.; Yang C.; Yang P.; The growth inhibitory effect of human gingiva-derived mesenchymal stromal cells expressing interferon-\u03b2 on tongue squamous cell carcinoma cells and xenograft model. Stem Cell Res Ther 2019,10(1),224","journal-title":"Stem Cell Res Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/gt.2008.101","volume":"15","author":"Ren C.","year":"2008","unstructured":"Ren C.; Kumar S.; Chanda D.; Cancer gene therapy using mesenchymal stem cells expressing interferon-\u03b2 in a mouse prostate cancer lung metastasis model. Gene Ther 2008,15(21),1446-1453","journal-title":"Gene Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"34172","DOI":"10.18632\/oncotarget.8997","volume":"7","author":"Shen C.J.","year":"2016","unstructured":"Shen C.J.; Chan T.F.; Chen C.C.; Hsu Y.C.; Long C.Y.; Lai C.S.; Human umbilical cord matrix-derived stem cells expressing interferon-\u03b2 gene inhibit breast cancer cells via apoptosis. Oncotarget 2016,7(23),34172-34179","journal-title":"Oncotarget"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41375-018-0373-9","volume":"33","author":"Lee M.W.","year":"2019","unstructured":"Lee M.W.; Ryu S.; Kim D.S.; Mesenchymal stem cells in suppression or progression of hematologic malignancy: Current status and challenges. Leukemia 2019,33(3),597-611","journal-title":"Leukemia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"318098","DOI":"10.1155\/2014\/318098","volume":"2014","author":"Yang X.","year":"2014","unstructured":"Yang X.; Du J.; Xu X.; Xu C.; Song W.; IFN-\u03b3-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the trail pathway. J Immunol Res 2014,2014,318098","journal-title":"J Immunol Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/hon.779","volume":"24","author":"Li X.","year":"2006","unstructured":"Li X.; Lu Y.; Huang W.; In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol 2006,24(3),151-158","journal-title":"Hematol Oncol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"Lazear H.M.","year":"2019","unstructured":"Lazear H.M.; Schoggins J.W.; Diamond M.S.; Shared and distinct functions of type I and type III interferons. Immunity 2019,50(4),907-923","journal-title":"Immunity"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2017.00304","volume":"8","author":"M\u00fcller L.","year":"2017","unstructured":"M\u00fcller L.; Aigner P.; Stoiber D.; Type I.; Type I interferons and natural killer cell regulation in cancer. Front Immunol 2017,8,304","journal-title":"Front Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1476-4598-13-255","volume":"13","author":"Bahrambeigi V.","year":"2014","unstructured":"Bahrambeigi V.; Ahmadi N.; Moisyadi S.; Urschitz J.; Salehi R.; Haghjooy Javanmard S.; PhiC31\/PiggyBac modified stromal stem cells: Effect of interferon \u03b3 and\/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma. Mol Cancer 2014,13(1),255","journal-title":"Mol Cancer"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3390\/ijms16011691","volume":"16","author":"Anestakis D.","year":"2015","unstructured":"Anestakis D.; Petanidis S.; Kalyvas S.; Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci 2015,16(1),1691-1710","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-017-0721-9","volume":"16","author":"Setrerrahmane S.","year":"2017","unstructured":"Setrerrahmane S.; Xu H.; Tumor-related interleukins: Old validated targets for new anti-cancer drug development. Mol Cancer 2017,16(1),153","journal-title":"Mol Cancer"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-319-53156-4_2","volume":"995","author":"Dhupkar P.","year":"2017","unstructured":"Dhupkar P.; Gordon N.; Interleukin-2: Old and new approaches to enhance immune-therapeutic efficacy. Adv Exp Med Biol 2017,995,33-51","journal-title":"Adv Exp Med Biol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1241323","DOI":"10.1155\/2018\/1241323","volume":"2018","author":"Zhou J.","year":"2018","unstructured":"Zhou J.; Liang T.; Wang D.; IFN \u03b1 -expressing amniotic fluid-derived mesenchymal stem cells migrate to and suppress HeLa cell-derived tumors in a mouse model. Stem Cells Int 2018,2018,1241323","journal-title":"Stem Cells Int"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1038\/onc.2016.128","volume":"35","author":"Shou P.","year":"2016","unstructured":"Shou P.; Chen Q.; Jiang J.; Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells. Oncogene 2016,35(46),5953-5962","journal-title":"Oncogene"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.prp.2019.01.013","volume":"215","author":"Chen X.","year":"2019","unstructured":"Chen X.; Wang K.; Chen S.; Chen Y.; Effects of mesenchymal stem cells harboring the Interferon-\u03b2 gene on A549 lung cancer in nude mice. Pathol Res Pract 2019,215(3),586-593","journal-title":"Pathol Res Pract"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/bioengineering7020059","volume":"7","author":"Chulpanova D.S.","year":"2020","unstructured":"Chulpanova D.S.; Solovyeva V.V.; James V.; Human mesenchymal stem cells overexpressing interleukin 2 can suppress proliferation of neuroblastoma cells in co-culture and activate mononuclear cells in vitro. Bioengineering 2020,7(2),59","journal-title":"Bioengineering"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.3892\/mmr.2015.4076","volume":"12","author":"You Q.","year":"2015","unstructured":"You Q.; Yao Y.; Zhang Y.; Fu S.; Du M.; Zhang G.; Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo. Mol Med Rep 2015,12(4),4859-4866","journal-title":"Mol Med Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.7150\/jca.38062","volume":"11","author":"Zhao C.","year":"2020","unstructured":"Zhao C.; Pu Y.; Zhang H.; IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J Cancer 2020,11(18),5345-5352","journal-title":"J Cancer"},{"key":"ref=65","first-page":"1517","volume":"22","author":"Wang H.","year":"2017","unstructured":"Wang H.; Wang J.; Shi X.; Ding Y.; Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-\u03b3 and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway. J Buon 2017,22(6),1517-1524","journal-title":"J Buon"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/1759-7714.12151","volume":"6","author":"Li X.","year":"2015","unstructured":"Li X.; Zhang P.; Liu X.; Lv P.; Expression of interleukin-12 by adipose-derived mesenchymal stem cells for treatment of lung adenocarcinoma. Thorac Cancer 2015,6(1),80-84","journal-title":"Thorac Cancer"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1600-0625.2006.00479.x","volume":"15","author":"Elzaouk L.","year":"2006","unstructured":"Elzaouk L.; Moelling K.; Pavlovic J.; Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006,15(11),865-874","journal-title":"Exp Dermatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ijc.29428","volume":"137","author":"Jeong K.Y.","year":"2015","unstructured":"Jeong K.Y.; Lee E.J.; Kim S.J.; Yang S.H.; Sung Y.C.; Seong J.; Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int J Cancer 2015,137(3),721-730","journal-title":"Int J Cancer"},{"key":"ref=69","first-page":"15840","volume":"8","author":"Wang A.","year":"2015","unstructured":"Wang A.; Zhou X.; Zhao J.; Liu T.; Xu J.; Therapeutic effects of bone marrow mesenchymal stem cells expressing interleukin-12 in mice bearing malignant ascites tumor. Int J Clin Exp Med 2015,8(9),15840-15845","journal-title":"Int J Clin Exp Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2010.187","volume":"22","author":"Ryu C.H.","year":"2011","unstructured":"Ryu C.H.; Park S.H.; Park S.A.; Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther 2011,22(6),733-743","journal-title":"Hum Gene Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cncr.24013","volume":"115","author":"Duan X.","year":"2009","unstructured":"Duan X.; Guan H.; Cao Y.; Kleinerman E.S.; Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 2009,115(1),13-22","journal-title":"Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/1535-7163.MCT-14-0175","volume":"13","author":"Jing W.","year":"2014","unstructured":"Jing W.; Chen Y.; Lu L.; Human umbilical cord blood-derived mesenchymal stem cells producing IL15 eradicate established pancreatic tumor in syngeneic mice. Mol Cancer Ther 2014,13(8),2127-2137","journal-title":"Mol Cancer Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.3892\/ol.2018.8166","volume":"15","author":"Liu X.","year":"2018","unstructured":"Liu X.; Hu J.; Li Y.; Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. Oncol Lett 2018,15(5),6265-6274","journal-title":"Oncol Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.cellbi.2008.07.023","volume":"33","author":"Xu G.","year":"2009","unstructured":"Xu G.; Jiang X.D.; Xu Y.; Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 2009,33(4),466-474","journal-title":"Cell Biol Int"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1089\/scd.2015.0103","volume":"24","author":"Kim N.","year":"2015","unstructured":"Kim N.; Nam Y.S.; Im K.I.; IL-21-expressing mesenchymal stem cells prevent lethal B-cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor. Stem Cells Dev 2015,24(23),2808-2821","journal-title":"Stem Cells Dev"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bab.63","volume":"58","author":"Hu W.","year":"2011","unstructured":"Hu W.; Wang J.; He X.; Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice. Biotechnol Appl Biochem 2011,58(6),397-404","journal-title":"Biotechnol Appl Biochem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1757-2215-7-8","volume":"7","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Wang J.; Ren M.; Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice. J Ovarian Res 2014,7(1),8","journal-title":"J Ovarian Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2147\/OTT.S147855","volume":"11","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Wang J.; Wu D.; IL-21-secreting hUCMSCs combined with miR-200c inhibit tumor growth and metastasis via repression of Wnt\/\u03b2-catenin signaling and epithelial-mesenchymal transition in epithelial ovarian cancer. OncoTargets Ther 2018,11,2037-2050","journal-title":"OncoTargets Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/jcp.29095","volume":"235","author":"Fan S.","year":"2020","unstructured":"Fan S.; Gao H.; Ji W.; Umbilical cord\u2010derived mesenchymal stromal\/stem cells expressing IL\u201024 induce apoptosis in gliomas. J Cell Physiol 2020,235(2),1769-1779","journal-title":"J Cell Physiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/1471-2407-14-713","volume":"14","author":"Suzuki T.","year":"2014","unstructured":"Suzuki T.; Kawamura K.; Li Q.; Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured. BMC Cancer 2014,14(1),713","journal-title":"BMC Cancer"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e000582","DOI":"10.1136\/jitc-2020-000582","volume":"8","author":"Iida Y.","year":"2020","unstructured":"Iida Y.; Yoshikawa R.; Murata A.; Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. J Immunother Cancer 2020,8(2),e000582","journal-title":"J Immunother Cancer"},{"key":"ref=82","first-page":"146","volume":"9","author":"Kenarkoohi A.","year":"2020","unstructured":"Kenarkoohi A.; Bamdad T.; Soleimani M.; Soleimanjahi H.; Fallah A.; Falahi S.; HSV-TK expressing mesenchymal stem cells exert inhibitory effect on cervical cancer model. Int J Mol Cell Med 2020,9(2),146-154","journal-title":"Int J Mol Cell Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"71112","DOI":"10.18632\/oncotarget.12737","volume":"7","author":"Yu Y.","year":"2016","unstructured":"Yu Y.; Zhang Q.; Meng Q.; Mesenchymal stem cells overexpressing Sirt1 inhibit prostate cancer growth by recruiting natural killer cells and macrophages. Oncotarget 2016,7(44),71112-71122","journal-title":"Oncotarget"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ijc.30846","volume":"141","author":"Zhang Q.","year":"2017","unstructured":"Zhang Q.; Yuan X.F.; Lu Y.; Surface expression of anti\u2010CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A\u2010engineered human umbilical cord mesenchymal stem cells. Int J Cancer 2017,141(7),1445-1457","journal-title":"Int J Cancer"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2017.07.002","volume":"6","author":"Szoor A.","year":"2017","unstructured":"Szoor A.; Vaidya A.; Velasquez M.P.; T cell-activating mesenchymal stem cells as a biotherapeutic for HCC. Mol Ther Oncolytics 2017,6,69-79","journal-title":"Mol Ther Oncolytics"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","volume":"10","author":"Zhang X.","year":"2017","unstructured":"Zhang X.; Yang Y.; Zhang L.; Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan. J Hematol Oncol 2017,10(1),56","journal-title":"J Hematol Oncol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Yang Y.","year":"2019","unstructured":"Yang Y.; Zhang X.; Lin F.; Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol 2019,12(1),46","journal-title":"J Hematol Oncol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1535-7163.MCT-18-0431","volume":"18","author":"Moreno R.","year":"2019","unstructured":"Moreno R.; Fajardo C.A.; Farrera-Sal M.; Enhanced antitumor efficacy of oncolytic adenovirus\u2013loaded menstrual blood\u2013derived mesenchymal stem cells in combination with peripheral blood mononuclear cells. Mol Cancer Ther 2019,18(1),127-138","journal-title":"Mol Cancer Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/cancers10110446","volume":"10","author":"Lu J.H.","year":"2018","unstructured":"Lu J.H.; Peng B.Y.; Chang C.C.; Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine. Cancers 2018,10(11),446","journal-title":"Cancers"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/mt.2011.152","volume":"19","author":"Wei H.J.","year":"2011","unstructured":"Wei H.J.; Wu A.T.H.; Hsu C.H.; The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine. Mol Ther 2011,19(12),2249-2257","journal-title":"Mol Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.18632\/oncotarget.27065","volume":"10","author":"Zeng Y.","year":"2019","unstructured":"Zeng Y.; Li B.; Li T.; CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer. Oncotarget 2019,10(43),4479-4491","journal-title":"Oncotarget"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/cells9040873","volume":"9","author":"Hombach A.A.","year":"2020","unstructured":"Hombach A.A.; Geumann U.; G\u00fcnther C.; Hermann F.G.; Abken H.; IL7-IL12 engineered Mesenchymal Stem Cells (MSCs) improve A CAR T cell attack against colorectal cancer cells. Cells 2020,9(4),873","journal-title":"Cells"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"Huang R.","year":"2020","unstructured":"Huang R.; Li X.; He Y.; Recent advances in CAR-T cell engineering. J Hematol Oncol 2020,13(1),86","journal-title":"J Hematol Oncol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"Sheth V.S.","year":"2021","unstructured":"Sheth V.S.; Gauthier J.; Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 2021,56(3),552-566","journal-title":"Bone Marrow Transplant"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"Schubert M.L.","year":"2021","unstructured":"Schubert M.L.; Schmitt M.; Wang L.; Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 2021,32(1),34-48","journal-title":"Ann Oncol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","volume":"12","author":"Acharya U.H.","year":"2019","unstructured":"Acharya U.H.; Dhawale T.; Yun S.; Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol 2019,12(3),195-205","journal-title":"Expert Rev Hematol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"Shimabukuro-Vornhagen A.","year":"2018","unstructured":"Shimabukuro-Vornhagen A.; G\u00f6del P.; Subklewe M.; Cytokine release syndrome. J Immunother Cancer 2018,6(1),56","journal-title":"J Immunother Cancer"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Hao Z.","year":"2020","unstructured":"Hao Z.; Li R.; Meng L.; Han Z.; Hong Z.; Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol 2020,9(1),15","journal-title":"Exp Hematol Oncol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","volume":"5","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Fang Y.; Chen X.; Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 2020,5(43),eaax7969","journal-title":"Sci Immunol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e9252","DOI":"10.1371\/journal.pone.0009252","volume":"5","author":"Maggini J.","year":"2010","unstructured":"Maggini J.; Mirkin G.; Bognanni I.; Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010,5(2),e9252","journal-title":"PLoS One"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.archoralbio.2018.11.007","volume":"98","author":"Hong R.","year":"2019","unstructured":"Hong R.; Wang Z.; Sui A.; Gingival mesenchymal stem cells attenuate pro-inflammatory macrophages stimulated with oxidized low-density lipoprotein and modulate lipid metabolism. Arch Oral Biol 2019,98,92-98","journal-title":"Arch Oral Biol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"107905","DOI":"10.1016\/j.exer.2019.107905","volume":"191","author":"Lu X.","year":"2020","unstructured":"Lu X.; Li N.; Zhao L.; Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype. Exp Eye Res 2020,191,107905","journal-title":"Exp Eye Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1080\/09168451.2018.1438167","volume":"82","author":"Jeong W.Y.","year":"2018","unstructured":"Jeong W.Y.; Kim J.H.; Kim C.W.; Co-culture of human bone marrow mesenchymal stem cells and macrophages attenuates lipopolysaccharide-induced inflammation in human corneal epithelial cells. Biosci Biotechnol Biochem 2018,82(5),800-809","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/scrt75","volume":"2","author":"Duffy M.M.","year":"2011","unstructured":"Duffy M.M.; Ritter T.; Ceredig R.; Griffin M.D.; Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011,2(4),34","journal-title":"Stem Cell Res Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","volume":"10","author":"Weiss A.R.R.","year":"2019","unstructured":"Weiss A.R.R.; Dahlke M.H.; Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 2019,10,1191","journal-title":"Front Immunol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/ijc.30265","volume":"139","author":"Ghosh T.","year":"2016","unstructured":"Ghosh T.; Barik S.; Bhuniya A.; Tumor-associated mesenchymal stem cells inhibit na\u00efve T cell expansion by blocking cysteine export from dendritic cells. Int J Cancer 2016,139(9),2068-2081","journal-title":"Int J Cancer"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e001419","DOI":"10.1136\/jitc-2020-001419","volume":"8","author":"Zanetti S.R.","year":"2020","unstructured":"Zanetti S.R.; Romecin P.A.; Vinyoles M.; Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. J Immunother Cancer 2020,8(2),e001419","journal-title":"J Immunother Cancer"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.ymthe.2021.02.004","volume":"29","author":"McKenna M.K.","year":"2021","unstructured":"McKenna M.K.; Englisch A.; Brenner B.; Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther 2021,29(5),1808-1820","journal-title":"Mol Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.reth.2021.05.007","volume":"18","author":"Kaffash Farkhad N.","year":"2021","unstructured":"Kaffash Farkhad N.; Reihani H.; sedaghat A, Moghadam AA, Moghadam AB, Tavakol-Afshari J. Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. Regen Ther 2021,18,152-160","journal-title":"Regen Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"726909","DOI":"10.3389\/fimmu.2021.726909","volume":"12","author":"Wang L.","year":"2021","unstructured":"Wang L.; Li Y.; Xu M.; Regulation of inflammatory cytokine storms by mesenchymal stem cells. Front Immunol 2021,12,726909","journal-title":"Front Immunol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/stem.3354","volume":"39","author":"Song N.","year":"2021","unstructured":"Song N.; Wakimoto H.; Rossignoli F.; Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells 2021,39(6),707-722","journal-title":"Stem Cells"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/sctm.18-0230","volume":"8","author":"Schweizer M.T.","year":"2019","unstructured":"Schweizer M.T.; Wang H.; Bivalacqua T.J.; A Phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer. Stem Cells Transl Med 2019,8(5),441-449","journal-title":"Stem Cells Transl Med"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","volume":"28","author":"Ruano D.","year":"2020","unstructured":"Ruano D.; L\u00f3pez-Mart\u00edn J.; Moreno L.; First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus icovir-5 in patients with advanced tumor. Molecular therapy 2020,28(4),1033-1042","journal-title":"Molecular therapy"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood-2010-06-287979","volume":"117","author":"El Haddad N.","year":"2011","unstructured":"El Haddad N.; Heathcote D.; Moore R.; Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood 2011,117(4),1176-1183","journal-title":"Blood"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1111\/j.1582-4934.2011.01509.x","volume":"16","author":"Schu S.","year":"2012","unstructured":"Schu S.; Nosov M.; O\u2019Flynn L.; Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012,16(9),2094-2103","journal-title":"J Cell Mol Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"0963689720965529","DOI":"10.1177\/0963689720965529","volume":"29","author":"Zha S.","year":"2020","unstructured":"Zha S.; Tay J.C.K.; Zhu S.; Li Z.; Du Z.; Wang S.; Generation of mesenchymal stromal cells with low immunogenicity from Human PBMC-derived \u03b22 microglobulin knockout induced pluripotent stem cells. Cell Transplant 2020,29,0963689720965529","journal-title":"Cell Transplant"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/stem.1563","volume":"32","author":"Giuliani M.","year":"2014","unstructured":"Giuliani M.; Bennaceur-Griscelli A.; Nanbakhsh A.; TLR ligands stimulation protects MSC from NK killing. Stem Cells 2014,32(1),290-300","journal-title":"Stem Cells"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood-2005-07-2775","volume":"107","author":"Spaggiari G.M.","year":"2006","unstructured":"Spaggiari G.M.; Capobianco A.; Becchetti S.; Mingari M.C.; Moretta L.; Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006,107(4),1484-1490","journal-title":"Blood"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3390\/ijms20081825","volume":"20","author":"Lee J.M.","year":"2019","unstructured":"Lee J.M.; When CAR meets stem cells. Int J Mol Sci 2019,20(8),1825","journal-title":"Int J Mol Sci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1021\/mp300261e","volume":"10","author":"Yan C.","year":"2013","unstructured":"Yan C.; Li S.; Li Z.; Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin\u2019s lymphoma. Mol Pharm 2013,10(1),142-151","journal-title":"Mol Pharm"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/term.228","volume":"4","author":"Balyasnikova I.V.","year":"2010","unstructured":"Balyasnikova I.V.; Franco-Gou R.; Mathis J.M.; Lesniak M.S.; Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med 2010,4(4),247-258","journal-title":"J Tissue Eng Regen Med"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1757-2215-3-12","volume":"3","author":"Komarova S.","year":"2010","unstructured":"Komarova S.; Roth J.; Alvarez R.; Curiel D.T.; Pereboeva L.; Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J Ovarian Res 2010,3(1),12","journal-title":"J Ovarian Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41417-018-0062-x","volume":"27","author":"Golinelli G.","year":"2020","unstructured":"Golinelli G.; Grisendi G.; Prapa M.; Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther 2020,27(7-8),558-570","journal-title":"Cancer Gene Ther"}],"container-title":["Current Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574888X18666230103120302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212345\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574888X18666230103120302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T18:36:04Z","timestamp":1693766164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212345\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":123,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574888x18666230103120302","relation":{},"ISSN":["1574-888X"],"issn-type":[{"value":"1574-888X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}